Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 10% vs MANNITOL 20%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular fluid, thereby reducing intracranial pressure and promoting diuresis.
Reduction of intracranial pressure and cerebral edema,Promotion of diuresis in patients with acute renal failure (oliguric phase) or to prevent renal failure in certain conditions,Reduction of intraocular pressure in acute glaucoma,Enhancement of urinary excretion of toxic substances (e.g., in overdoses),Adjunct in dialysis or hemofiltration (off-label)
Reduction of intracranial pressure and cerebral edema,Reduction of intraocular pressure,Promotion of diuresis in acute renal failure (off-label)
0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.
Adult: 50-100 g intravenously as a 20% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV over 30-60 minutes. For oliguric acute kidney injury: test dose 0.2 g/kg IV over 3-5 minutes.
Terminal half-life: 1.1–1.6 hours; prolonged to 6–36 hours in renal impairment
Terminal elimination half-life 1.1–1.6 hours in normal renal function; prolonged to 18–36 hours in anuria/end-stage renal disease.
Mannitol is not metabolized in the body. It is eliminated unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Minimal hepatic metabolism; primarily excreted unchanged by the kidneys.
Renal: 90% as unchanged drug; <10% metabolized in liver to fructose and glucose; fecal: negligible
Renal, >90% unchanged by glomerular filtration; negligible biliary (<2%) or fecal elimination.
Negligible (<2%); does not bind to plasma proteins
Negligible (<0.1%); does not bind significantly to plasma proteins.
0.36–0.5 L/kg; distributes primarily in extracellular fluid, limited CNS penetration due to hydrophilic nature
0.25–0.4 L/kg; corresponds to extracellular fluid volume; increased in dehydration, decreased in hypervolemia.
IV: 100%; oral: negligible (<10%) due to poor absorption and osmotic diarrhea
Intravenous: 100%; oral: <10% (non-absorbed, acts as osmotic laxative).
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolality.
GFR < 50 m L/min: avoid use due to risk of volume overload and hyperosmolality. GFR 50-80 m L/min: use with caution, monitor serum osmolarity. No specific dose reduction established.
No specific Child-Pugh based adjustment required; use with caution in severe hepatic impairment due to risk of fluid overload.
No adjustment required for Child-Pugh class A or B. Child-Pugh class C: use with caution due to potential fluid and electrolyte imbalances; monitor closely.
0.25-1 g/kg intravenously as a 10% solution over 30-60 minutes, repeated every 6-8 hours as needed.
For cerebral edema: 0.25-1 g/kg IV as a 20% solution over 30-60 minutes. For elevated intracranial pressure: 0.25-0.5 g/kg IV. Maximum single dose typically 2 g/kg.
Start at lower end of dosing range (0.25-0.5 g/kg) due to decreased renal function; monitor fluid and electrolyte balance closely.
Elderly patients: lower initial doses (e.g., 25-50 g) recommended due to decreased renal function and higher risk of electrolyte disturbances. Monitor serum osmolarity and renal function closely.
None
None
Use with caution in patients with congestive heart failure due to risk of pulmonary edema from fluid overload,Monitor serum electrolytes (especially sodium and potassium) and renal function during therapy,May cause acute kidney injury with excessive doses or pre-existing renal impairment,In patients with intracranial hemorrhage, avoid rapid reduction of intracranial pressure,May cause expansion of extracellular fluid volume leading to pulmonary edema in patients with compromised cardiac function
May cause volume expansion, electrolyte imbalances, and renal impairment; monitor serum electrolytes, osmolality, and renal function; use with caution in patients with heart failure or pulmonary congestion.
Anuria due to severe renal disease,Severe pulmonary edema or congestion,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, and known hypersensitivity.
Avoid high-sodium foods and salt substitutes to prevent electrolyte imbalance; maintain adequate fluid intake unless fluid restriction is advised; no specific food interactions, but monitor for changes in blood glucose if diabetic.
No known food interactions; however, monitor fluid and electrolyte balance as mannitol induces diuresis.
Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with clinical use is low. Second trimester: Generally safe for short-term use when indicated (e.g., elevated intracranial pressure), but avoid prolonged exposure to prevent fetal dehydration or electrolyte imbalances. Third trimester: Use cautiously; osmotic diuresis may cause maternal hypovolemia, potentially reducing placental perfusion and leading to fetal distress.
Mannitol is not teratogenic in animal studies. In human pregnancy, there are no controlled studies; FDA pregnancy category C. First trimester: theoretical risk due to osmotic shifts, but no documented fetal harm. Second and third trimesters: use only if clearly needed; may cause maternal dehydration and electrolyte disturbances, potentially affecting fetal fluid balance. Avoid in severe maternal renal impairment.
Mannitol is excreted into breast milk in low concentrations (estimated M/P ratio <0.1) due to its high molecular weight and hydrophilicity. Oral bioavailability in infants is negligible, and no adverse effects have been reported. However, caution is advised if used repeatedly or in high doses, as theoretical risk of neonatal electrolyte imbalance exists.
Mannitol is excreted into breast milk in trace amounts; M/P ratio not established. Oral bioavailability is low, so infant exposure via breastfeeding is minimal. Compatible with breastfeeding; caution if infant has renal impairment.
Pregnancy does not significantly alter the pharmacokinetics of mannitol. Standard adult dosing (0.25–2 g/kg as a 10% solution) is recommended, with adjustments based on renal function, volume status, and therapeutic response. Avoid excessive doses to prevent maternal volume overload and electrolyte disturbances.
No specific dose adjustments required; pharmacokinetics of mannitol are not significantly altered by pregnancy. Use standard dosing based on indication and renal function. Caution in preeclampsia due to potential for fluid shifts.
Administer via in-line filter to prevent crystallization; monitor serum sodium and osmolality closely to avoid hypernatremia and osmotic demyelination; ensure adequate urine output before use to avoid pulmonary edema; use with caution in patients with congestive heart failure or renal impairment; can cause transient volume expansion followed by diuresis.
Monitor serum osmolarity and sodium levels frequently; avoid use in patients with anuria, severe pulmonary congestion, or intracranial hemorrhage. Mannitol may cause acute kidney injury if used in high doses or in patients with pre-existing renal impairment. Administer via in-line filter to prevent crystallization.
This medication may cause increased thirst and frequent urination.,Report any chest pain, difficulty breathing, or swelling of ankles/legs.,Avoid consuming salty foods to prevent fluid retention.,Do not stop taking without consulting your doctor.,Inform your doctor if you have kidney disease, heart failure, or are on a low-salt diet.
This medication is given intravenously to reduce swelling in the brain or to promote urine output.,Report any signs of allergic reaction, chest tightness, or difficulty breathing immediately.,You may experience increased thirst, headache, or nausea during infusion.,Inform your healthcare provider if you have kidney problems, heart failure, or are pregnant.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 10% vs MANNITOL 20%, answered by our medical review team.
MANNITOL 10% is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.. MANNITOL 20% is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular fluid, thereby reducing intracranial pressure and promoting diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 10% and MANNITOL 20% depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 10% is: 0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.. The standard adult dose of MANNITOL 20% is: Adult: 50-100 g intravenously as a 20% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV over 30-60 minutes. For oliguric acute kidney injury: test dose 0.2 g/kg IV over 3-5 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining MANNITOL 10% and MANNITOL 20%. Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. MANNITOL 10% is classified as Category A/B. Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with c. MANNITOL 20% is classified as Category A/B. Mannitol is not teratogenic in animal studies. In human pregnancy, there are no controlled studies; FDA pregnancy category C. First trimester: theoretical risk due to osmotic shift. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.